Login to Your Account

Overall, Progression-Free Survival Benefits

Plexxikon BRIMs with Joy over PLX4032 Phase III Data

By Anette Breindl

Thursday, January 20, 2011
Melanoma drug PLX4032 has set the cancer world abuzz more than once over the past year and a half. And with an interim analysis of a Phase III trial released yesterday that showed both an overall survival benefit and a progression-free survival benefit for patients taking the drug as a first-line agent, it is doing it again.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription